Health Care Technology

Phreesia

Phreesia to Release FY2027 Q1 Earnings on May 27 After-Market (EST), Forecast Revenue USD 130.07 M, EPS USD 0.0155

RBC Capital Analyst Reiterates Buy Rating for Phreesia

Pale Fire Capital Increases Stake in Phreesia to 8.92 Million Shares

Phreesia released FY2026 Annual Earnings on March 30 After-Market (EST), actual revenue USD 480.59 M (forecast USD 480.13 M), actual EPS USD 0.0386 (forecast USD 0.076)

Phreesia released FY2026 Q4 earnings on March 30 After-Market EST, actual revenue USD 127.07 M (forecast USD 126.63 M), actual EPS USD 0.0199 (forecast USD 0.0603)

Phreesia to Release FY2026 Q4 Earnings on March 30 After-Market EST, Forecast Revenue USD 126.71 M, EPS USD 0.0612

Phreesia Inc. CFO Reports Sale of Common Stock

Phreesia released FY2026 Q3 earnings on December 9 After-Market EST, actual revenue USD 120.33 M (forecast USD 120.03 M), actual EPS USD 0.0699 (forecast USD 0.0028)

Phreesia released FY2026 9 Months Earnings on December 9 After-Market EST, actual revenue USD 353.52 M, actual EPS USD 0.0135

Phreesia Inc. Completes USD 160 Million Acquisition of AccessOne

Phreesia Inc. Reports Q3 Earnings, Reversing Year-Over-Year Losses

Phreesia to Release FY2026 Q3 Earnings on December 8 After-Market EST, Forecast Revenue USD 120.03 M, EPS USD 0.0028

Phreesia Inc. Executives Sell Common Stock

Phreesia Recognized in Capterra Shortlist

Canaccord Genuity Maintains Buy Rating on Phreesia with a Price Target of $38

Voya Investment Management LLC Reduced Holdings in Phreesia, Inc.

Six analysts rate Phreesia stock

Phreesia released FY2026 Semi-Annual earnings on September 4 After-Market (EST), actual revenue USD 233.19 M, actual EPS USD -0.0599

Phreesia released FY2026 Q2 earnings on September 4 After-Market EST, actual revenue USD 117.26 M (forecast USD 116.38 M), actual EPS USD 0.0099 (forecast USD -0.0669)

Phreesia Inc. Reports 15% Revenue Growth in Q2 FY2026 with First-Ever Net Income

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

Earning Release Date

财报预告

FY2027 Q1 Earning Release 2026.05.27 (EST) After-Market

Rosen Law Firm has announced a class action lawsuit for Phreesia, Inc. investors who purchased stock between May 8, 2025, and March 30, 2026. Investors may be entitled to compensation without upfront costs. A lead plaintiff must be appointed by July 13, 2026. The lawsuit alleges that Phreesia misled investors about its demand and revenue streams, leading to damages when the truth emerged.

prnewswire

21:15 ETPHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit

Phreesia (NYSE: PHR) stock fell 3.5% despite a positive market, following a downgrade by Wells Fargo analyst Stan Berenshteyn, who changed his rating to 'hold' and cut the price target from $15 to $9. The downgrade was attributed to increased competition and concerns over subscription revenue. While Berenshteyn highlighted vulnerabilities in Phreesia's client base, some analysts remain optimistic about the company's long-term prospects.

nasdaq

S&P 500

Wells Fargo

NVIDIA

Intel

Netflix

Nasdaq

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

NVIDIA Corporation

Why Phreesia Stock Got Clocked Today

Phreesia (NYSE:PHR) shares gapped down from $9.17 to $8.84, currently trading at $8.7870. Negative sentiment arises from a class action lawsuit, impacting management credibility. Analysts have lowered price targets, with Wells Fargo setting it at $9.00 and JPMorgan at $16.00. The company reported Q1 earnings of $0.02 EPS, missing estimates. Insider selling has occurred, with insiders owning 5.50% of shares. Institutional trading activity has also been noted.

Market Beat

JPMorgan Chase

Waystar

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Phreesia (NYSE:PHR) Shares Gap Down   - Here's Why

Phreesia (NYSE:PHR) is set to announce its Q1 2027 earnings on May 27, with analysts predicting earnings of $0.02 per share and revenue of $130.08 million. The company recently reported $0.02 EPS for Q1 2026, missing estimates. Phreesia's stock has seen a price target reduction from various analysts, with an average target of $20.00. Legal scrutiny continues to affect sentiment, as multiple law firms remind investors of ongoing securities class actions.

Barclays

Bank of Montreal

Phreesia (PHR) Projected to Post Earnings on Wednesday

Barclays has downgraded Phreesia (NYSE:PHR) from a 'strong-buy' to a 'hold' rating. Other analysts have also adjusted their ratings and target prices, with Mizuho lowering its target from $22 to $19 and DA Davidson from $35 to $30. Phreesia's stock has a consensus rating of 'Moderate Buy' and a target price of $20. The company reported a quarterly EPS of $0.02, missing estimates, with revenue of $127.07 million, up 15.9% year-over-year.

Mizuho Financial

Mizuho Financial Group, Inc.

Citizens Financial

Citigroup

Raymond James Financial

AllianceBernstein

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

CITIGROUP INC 6.250 NON CUM SER II PFD WI

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Phreesia (NYSE:PHR) Stock Rating Lowered by Barclays

Robbins LLP has announced a class action lawsuit on behalf of investors who purchased Phreesia, Inc. (NYSE: PHR) stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors about the sustainability of growth in its Network Solutions business and its fiscal 2027 revenue outlook. Following a revenue outlook downgrade, Phreesia's stock price fell approximately 27%. Shareholders interested in participating in the class action must submit their papers by July 13, 2026.

18:35 ETPHR Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against Phreesia, Inc.

Faruqi & Faruqi, LLP is investigating potential claims against Phreesia, Inc. (NYSE: PHR) and reminds investors of the July 13, 2026 deadline to seek lead plaintiff status in a federal securities class action. The firm alleges that Phreesia made misleading statements regarding its financial performance, leading to a significant stock price drop. Investors who suffered losses between May 8, 2025, and March 30, 2026, are encouraged to contact the firm for legal options. The firm has a history of recovering substantial amounts for investors since its establishment in 1995.

15:30 ETPHR INVESTOR NOTICE: Faruqi & Faruqi, LLP Notifies Phreesia (PHR) Investors of Securities Class Action Deadline on July 13, 2026

Phreesia(PHR.US)